In our weekly expert view piece, Chris Pettigrew of Novasecta, looks at the pros and cons of the Bayer/Monsanto deal.
Bayer’s huge intended purchase of Monsanto for $66 billion indicates a renewed focus on crop science and ipso facto a relative deprioritisation of investment in its healthcare business.
As Bayer’s crop science sales swing from ~30% currently to ~50% pro forma for the merged entity, investors who once considered Bayer a healthcare company may question this new emphasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze